Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab plus whole-brain radiotherapy for non-small cell lung cancer with brain metastases
ACTRN12610000560099Phase 2Recruiting
- Sponsor
- YM BioSciences
- Start
- Sep 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) and brain metastases comparing Nimotuzumab + whole-brain radiotherapy with Placebo + whole-brain radiotherapy (2 arms). Primary endpoint: Intracranial disease progression over 6 months. Started Sep 2009; status: recruiting.
02
Drugs
nimotuzumab
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on ACTRN12610000560099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000560099.